IL-1 vaccination is suitable for treating inflammatory diseases

Frontiers in Pharmacology

Volumn 8, Issue JAN, 2017, Pages

  Assier, Eric ^a,b   Bessis, Natacha ^a,b   Zagury, Jean François ^c   Boissier, Marie Christophe ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c University of Paris Cité   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chronic disease; Cytokines; IL 1; Inflammation; Vaccination

Indexed keywords

ANAKINRA; CANAKINUMAB; INTERLEUKIN 1; INTERLEUKIN 1BETA; RILONACEPT;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CANCER REGRESSION; CELLULAR IMMUNITY; CHONDROCALCINOSIS; CHRONIC DISEASE; CINCA SYNDROME; COLLAGEN ANTIBODY-INDUCED ARTHRITIS; CYTOKINE PRODUCTION; DRUG MECHANISM; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; INFLAMMATION; MASS IMMUNIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS;

EID: 85012061626     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00006     Document Type: Note

References (39)

1. Assier, E., Belmellat, N., Semerano, L., Ryffel, B., Decker, P., Quesniaux, V., et al. (2016). Anti-TNF vaccination protects from experimental Arthritis without affecting resistance to Mycobacterium tuberculosis or Listeria monocytogenes infection [abstract]. Arthritis Rheumatol. 68(Suppl. 10). Available online at: http://acrabstracts.org/abstract/anti-tnf-vaccination-protects-from-experimental-arthritis-without-affecting-resistance-to-mycobacterium-tuberculosis-or-listeria-monocytogenes-infection/
2. Assier, E., Semerano, L., Duvallet, E., Delavallée, L., Bernier, E., Laborie, M., et al. (2012). Modulation of anti-tumor necrosis factor alpha (TNF-a) antibody secretion in mice immunized with TNF-a kinoid. Clin. Vaccine Immunol. 19, 699-703. doi: 10.1128/CVI.05649-11
3. Bertin-Maghit, S. M., Capini, C. J., Bessis, N., Chomilier, J., Muller, S., Abbas, A., et al. (2005). Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 22, 3144-3153. doi: 10.1016/j.vaccine.2005.03.030
4. Biton, J., Semerano, L., Delavallée, L., Lemeiter, D., Laborie, M., Grouard-Vogel, G., et al. (2011). Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J. Immunol. 186, 3899-3910. doi: 10.4049/jimmunol.1003372
5. Bossù, P., Neumann, D., Del Giudice, E., Ciaramella, A., Gloaguen, I., Fantuzzi, G., et al. (2003). IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 100, 14181-14186. doi: 10.1073/pnas.2336094100
6. Capini, C. J., Bertin-Maghit, S. M., Bessis, N., Haumont, P. M., Bernier, E. M., Muel, E. G., et al. (2004). Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 22, 3144-3153. doi: 10.1016/j.vaccine.2004.01.064
7. Cavalli, G., and Dinarello, C. A. (2015). Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 54, 2134-2144. doi: 10.1093/rheumatology/kev269
8. Cavelti-Weder, C., Timper, K., Seelig, E., Keller, C., Osranek, M., Lässing, U., et al. (2016). Development of an Interleukin-1β vaccine in patients with Type 2 Diabetes. Mol. Ther. 24, 1003-1012. doi: 10.1038/mt.2015.227
9. Chackerian, B., Lowy, D. R., and Schiller, J. T. (2001). Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108, 415-423. doi: 10.1172/JCI11849
10. Dalum, I., Butler, D. M., Jensen, M. R., Hindersson, P., Steinaa, L., Waterston, A. M., et al. (1999). Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 17, 666-669. doi: 10.1038/10878
11. Delavallée, L., Le Buanec, H., Bessis, N., Assier, E., Denys, A., Bizzini, B., et al. (2008). Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFa) transgenic mice vaccinated against TNFalpha. Ann. Rheum. Dis. 67, 1332-1338. doi: 10.1136/ard.2007.079137
12. Desallais, L., Avouac, J., Fréchet, M., Elhai, M., Ratsimandresy, R., Montes, M., et al. (2014). Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res. Ther. 16:R157. doi: 10.1186/ar4672
13. Desallais, L., Bouchez, C., Mouhsine, H., Moreau, G., Ratsimandresy, R., Montes, M., et al. (2016). Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the delayed-type hypersensitivity reaction in cynomolgus monkeys. Sci. Rep. 6:19549. doi: 10.1038/srep19549
14. Ducreux, J., Houssiau, F. A., Vandepapelière, P., Jorgensen, C., Lazaro, E., Spertini, F., et al. (2016). Interferon a kinoid induces neutralizing anti-interferon a antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon a kinoid phase I/II study. Rheumatology (Oxford) 55, 1901-1905. doi: 10.1093/rheumatology/kew262
15. Durez, P., Vandepapeliere, P., Miranda, P., Toncheva, A., Berman, A., Kehler, T., et al. (2014). Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS ONE 9:e113465. doi: 10.1371/journal.pone.0113465
16. Galle, P., Jensen, L., Andersson, C., Cuzzocrea, S., Di Paola, R., Nicoletti, F., et al. (2007). Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int. Immunopharmacol. 7, 1704-1713. doi: 10.1016/j.intimp.2007.08.026
17. Guan, Q., Burtnick, H. A., Qing, G., Weiss, C. R., Ma, A. G., Ma, Y., et al. (2013). Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis. Immunotherapy 5, 1313-1322. doi: 10.2217/imt.13.141
18. Lauwerys, B. R., Hachulla, E., Spertini, F., Lazaro, E., Jorgensen, C., Mariette, X., et al. (2013). Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon a-kinoid. Arthritis Rheum. 65, 447-456. doi: 10.1002/art.37785
19. Le Buanec, H., Delavallée, L., Bessis, N., Paturance, S., Bizzini, B., Gallo, R., et al. (2006). TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFa protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 103, 19442-19447. doi: 10.1073/pnas.0604827103
20. Mathian, A., Amoura, Z., Adam, E., Colaone, F., Hoekman, M. F., Dhellin, O., et al. (2011). Active immunisation of human interferon a transgenic mice with a human interferon a Kinoid induces antibodies that neutralise interferon a in sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1138-1143. doi: 10.1136/ard.2010.141101
21. McInnes, I. B., and Schett, G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442. doi: 10.1038/nri2094
22. Ratsimandresy, R. A., Duvallet, E., Assier, E., Semerano, L., Delavallée, L., Bessis, N., et al. (2011). Active immunization against IL-23p19 improves experimental arthritis. Vaccine 29, 9329-9336. doi: 10.1016/j.vaccine.2011.09.134
23. Richette, P., and Bardin, T. (2010). Gout. Lancet 375, 318-328. doi: 10.1016/S0140-6736(09)60883-7
24. Rodríguez-álvarez, Y., Morera-Díaz, Y., Gerónimo-Pérez, H., Castro-Velazco, J., Martínez-Castillo, R., Puente-Pérez, P., et al. (2016). Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates. BMC Immunol. 17:30. doi: 10.1186/s12865-016-0168-6
25. Röhn, T. A., Jennings, G. T., Hernandez, M., Grest, P., Beck, M., Zou, Y., et al. (2006). Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36, 2857-2867. doi: 10.1002/eji.200636658
26. Semerano, L., Assier, E., and Boissier, M. C. (2012). Anti-cytokine vaccination: a new biotherapy of autoimmunity? Autoimmun. Rev. 11, 785-786. doi: 10.1016/j.autrev.2012.02.003
27. Semerano, L., Biton, J., Delavallée, L., Duvallet, E., Assier, E., Bessis, N., et al. (2013). Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-a immunotherapy in human TNF-a transgenic mice depends on anti-TNF-a antibody levels. Clin. Exp. Immunol. 172, 54-62. doi: 10.1111/cei.12040
28. Semerano, L., Duvallet, E., Belmellat, N., Marinval, N., Schall, N., Monteil, M., et al. (2016b). Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis. Angiogenesis 19, 39-52. doi: 10.1007/s10456-015-9487-0
29. Semerano, L., Minichiello, E., Bessis, N., and Boissie, M. C. (2016a). Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol. Med. 22, 214-229. doi: 10.1016/j.molmed.2016.01.005
30. Shen, Y., Chen, J., Zhang, X., Wu, X., and Xu, Q. (2007). Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int. Immunopharmacol. 7, 1140-1149. doi: 10.1016/j.intimp.2007.04.009
31. Sonderegger, I., Röhn, T. A., Kurrer, M. O., Iezzi, G., Zou, Y., Kastelein, R. A., et al. (2006). Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 36, 2849-2856. doi: 10.1002/eji.200636484
32. Spohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beck, M., et al. (2007). A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178, 7450-7457. doi: 10.4049/jimmunol.178.11.7450
33. Spohn, G., Keller, I., Beck, M., Grest, P., Jennings, G. T., and Bachmann, M. F. (2008). Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38, 877-887. doi: 10.1002/eji.200737989
34. Spohn, G., Schori, C., Keller, I., Sladko, K., Sina, C., Guler, R., et al. (2014). Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol. Ther. Methods Clin. Dev. 1:14048. doi: 10.1038/mtm.2014.48
35. Sun, J. H., Zhang, Y. H., Kuang, J. Y., Liu, G., Liu, Y. X., and Liu, B. H. (2016). Active immunisation targeting soluble murine tumour necrosis factor alpha is safe and effective in collagen-induced arthritis model treatment. Clin. Exp. Rheumatol. 34, 242-246.
36. Uyttenhove, C., and Van Snick, J. (2006). Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 36, 2868-2874. doi: 10.1002/eji.200636662
37. Wildbaum, G., Youssef, S., and Karin, N. (2000). A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J. Immunol. 165, 5860-5866. doi: 10.4049/jimmunol.165.10.5860
38. Zagury, D., Le Buanec, H., Mathian, A., Larcier, P., Burnett, R., Amoura, Z., et al. (2009). IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc. Natl. Acad. Sci. U.S.A. 106, 5294-5299. doi: 10.1073/pnas.0900615106
39. Zhang, L., Wang, J., Xu, A., Zhong, C., Lu, W., Deng, L., et al. (2016). A rationally designed TNF-a epitope-scaffold immunogen induces sustained antibody response and alleviates collagen-induced arthritis in mice. PLoS ONE 11:e0163080. doi: 10.1371/journal.pone.0163080